we generated cell lines that constitutively or through induction with doxycycline express R11.1.6 or a control protein YW1 and show specific binding by R11.1.6 to endogenous Ras through microscopy and co-immunoprecipitation experiments. Genetically-encoded intracellular expression of this high-affinity Ras antagonist, however, fails to measurably disrupt signaling through either the MAPK or PI3K pathway. Consistently, cellular proliferation was unaffected as well. To understand this lack of signaling inhibition, we quantified the number of molecules of R11.1.6 expressed by the inducible cell lines and developed a simple mathematical model describing the competitive binding of Ras by R11.1.6 and Raf. This model supports a potential mechanism for the lack of biological effects that we observed, suggesting stoichiometric and thermodynamic barriers that should be overcome in pharmacological efforts to directly compete with downstream effector proteins localized to membranes at very high effective concentrations.
supplemented with 10% FBS (Life Technologies), 100 units/mL penicillin, and 100 μg/mL streptomycin (Life Technologies) and was purchased from ATCC and Life Technologies. Cell lines transduced to stably express R11.1.6, YW1, EGFP, or EGFP fusions of R11.1.6/YW1 were cultured in the media as indicated above. Cell lines transduced to express EGFP fusions of R11.1.6/YW1 under an inducible promoter were cultured in the media as indicated above, but without penicillin/streptomycin and with Tet System Approved FBS (Clontech) and 1-4 μg/mL puromycin (Life Technologies). All cell lines were maintained at 37°C and 5% CO2 and were authenticated by the manufacturer and tested for mycoplasma contamination to meet standard levels. Cell lines were passaged a minimum of five times and up to fifteen times before use.
Subcloning. For constitutive expression, R11.1.6 and YW1 were cloned into lentiviral vector pLJM1-EGFP (Addgene plasmid #19319) using In-Fusion Cloning (Clontech) according to the manufacturer's instructions. Cmyc-R11.1.6 and cmyc-YW1 were cloned into a modified version of the lentiviral vector pLJM1, in which protein expression is under the CMV promoter and EGFP under the PGK promoter, using In-Fusion Cloning (Clontech) according to the manufacturer's instructions. For inducible expression, the sequences for EGFP-R11.1.6 and EGFP-YW1 were PCR amplified, digested with AgeI and NheI, and cloned into AgeI-and NheIdigested lentiviral pCW57.1 (Addgene plasmid #41393) vector. Cloning and DNA preparations were done using One Shot Stbl3 cells (Thermo Fisher Scientific). plates with pLJM1 or modified pLJM1 plasmids (into which had been cloned cmyc-or EGFP-R11.1.6 or -YW1) and packaging plasmids using calcium phosphate. Approximately 24 hours following transfection, media containing virus particles was harvested and filtered through a 0.45-um filter. To generate VSV-G pseudotyped lentiviral particles using the pCW57.1 doxycycline-inducible expression plasmid, third generation packaging plasmids were used. HEK 293T cells were transiently transfected in 10-cm plates with pCW57.1 plasmid (into which had been cloned EGFP-R11.1.6 or -YW1) and packaging plasmids using Fugene transfection reagent (Roche). After approximately 72 hours, media containing virus particles was harvested and centrifuged to remove cell debris.
To transduce cancer cell lines with pLJM1 lentiviral particles, cells to be infected were plated in 12-well plates and adhered overnight. Filtered virus harvested from the HEK 293T transient transfection was added at 1 mL/well and incubated for approximately 24 hours, after which virus-containing media was replaced with complete media as described above. To transduce cancer cell lines with pCW57.1 inducible lentiviral particles, cells to be infected were plated in 6-well plates and adhered overnight. Centrifuged virus harvested from the HEK 293T transient transfection was added at 0.5 mL/well to 1 mL/well complete media supplemented with polybrene (Sigma) at 5 ug/mL final concentration. Cells were transduced overnight at 37C.
To select successfully transduced cells with the pLJM1 viral particles, cells were sorted either once or twice based on EGFP expression using a FACS Aria IIU (BD Biosciences).
Successfully transduced cells with the inducible pCW57.1 viral particles were selected using puromycin (Life Technologies) at 4 or 5 μg/mL final concentration. Selected cells were induced with doxycycline (Sigma) for 48 hours and read on a BD ACCURI C6 flow cytometer for EGFP expression. Flow cytometry data were analyzed using FlowJo software. Fluorescence microscopy. Lentivirus-generated stable cell lines were plated on #1 glass cover slips (Chemglass) and adhered overnight. Approximately 24 hours after plating, cells were fixed with 4% paraformaldehyde for 10 minutes at room temperature and cover slips mounted with DAPI-containing mounting medium (Vectashield, Vector Laboratories) and dried overnight.
Lentivirus-generated inducible stable cell lines were plated on #1 glass cover slips (Chemglass) and adhered overnight. Cells were induced with doxycycline (Sigma) at 2 μg/mL final concentration for 48 hours and then fixed with 4% paraformaldehyde for 10 minutes at room temperature and cover slips mounted with DAPI-containing mounting medium (Vectashield, Vector Laboratories) and dried overnight. Images were acquired at room temperature using a GE (Applied Precision) DeltaVision Spectris inverted Olympus X71 microscope with a 60x objective lens, captured with a Photometrics CoolSNAP HQ camera. SoftWoRx software was used for image acquisition and deconvolution. EGFP signal used the ex. 475/em. 528 filter set. Cell signaling assay. Lentivirus-generated stable cell lines were plated and adhered overnight, and then serum-starved overnight. Human EGF (Peprotech) was added at a final concentration of 1 nM for 5 minutes, after which cells were washed on ice and lysed in protease inhibitor (cOmplete EDTA-free protease inhibitor cocktail, Roche) containing RIPA lysis buffer (Abcam).
Lentivirus-generated inducible stable cell lines were plated and adhered overnight. Cells were induced with doxycycline (Sigma) at 125, 250, 500, 1000, or 2000 ng/mL final concentration for 48 hours at 37C. Cells were washed on ice and lysed in protease inhibitor (cOmplete EDTAfree protease inhibitor cocktail, Roche) containing RIPA lysis buffer (Abcam). Whole cell lysates were analyzed by western blot for activation of MEK, ERK, and/or AKT with phosphospecific antibodies.
Proliferation assay. Stable cell line proliferation was measured using a WST-1-based colorimetric assay according to the manufacturer's instructions (Roche). Cells were seeded in flat-bottom 96-well plates and incubated for 24, 48, or 72 hours at 37°C and 5% CO2, after which proliferation was determined. In some assays, PI3K inhibitors wortmannin (Sigma) or ZSTK474 (kind gift from the White lab, MIT) were added to cells for 24 hours, after which proliferation was determined. show clear peripheral membrane staining, consistent with binding to Ras which localizes to the inner plasma membrane (Fig. 1a) . Diffuse cytoplasmic fluorescence further indicates that sufficient excess of the EGFP-R11.1.6 fusion is present to avoid significant depletion upon binding to membrane-localized Ras. This membrane localization is not observed for control cell lines expressing EGFP-YW1 or EGFP only. We next investigated the effects of R11.1.6 expression on endogenous Ras-driven signaling (Fig. 1b) . Curiously, we observed no inhibition in either the MAPK or PI3K pathway, as evidenced by no changes in phosphorylation of MEK, ERK, or AKT (Ser473) in the presence of R11.1.6. This lack of signaling inhibition expectedly translated into unchanged levels of cellular proliferation (Fig. 1c) , ability to form colonies ( Supplementary Fig. S2a ), and growth in soft agar. We thought that combination of R11.1.6-mediated Ras antagonism and PI3K inhibition via small molecule inhibitors wortmannin and ZSTK474 may result in greater slowing of growth for the R11.1.6-expressing cell lines compared to controls, but found that across a range of concentrations of added inhibitor, there was no difference in proliferation between the cell lines attributable to R11.1.6 expression ( Supplementary Fig. S2b ).
We observed that cell lines transduced to stably express R11.1.6 maintained EGFP signal over the course of 30 days (Supplementary Fig. S2c ), suggesting that presence of R11.1.6 does not affect proliferation even after considerable time has passed. Because cancer cells are known to develop resistance to chemotherapy and targeted therapy (20) 
upregulate alternative pathways in response to targeted inhibitors (21), we hypothesized that the cell lines had circumvented R11.1.6 antagonism through amplification of other pathways. To mitigate the potential for resistance inherent in constitutive expression, we expanded our panel of human cancer cell lines (Table 1 ) and generated stable cell lines that express EGFP fusions of R11.1.6 or YW1 under an inducible promoter, so that only upon addition of doxycycline is there cytoplasmic expression.
Selected cell lines showed no leaky expression in the absence of doxycycline and induction of EGFP fused proteins at the highest doxycycline concentration (Supplementary Fig.   S3 ). Consistent with our constitutively expressing stable cell lines (Fig. 1a) , we observed membrane localization in the panel of inducible cell lines expressing EGFP-R11.1.6, but not the EGFP-YW1 control (Fig. 2a) . Specific binding to Ras was confirmed by coimmunoprecipitation, showing that the cell lines induced to express EGFP-R11.1.6 pull down Ras while those expressing EGFP-YW1 do not (Fig. 2b) . Having confirmed binding of Ras by R11.1.6, we next investigated its effects on downstream signaling, probing for phosphorylation of ERK 48 hours following induction of expression (Fig. 2c) . Again, we failed to observe any inhibition of signaling in response to R11.1.6-mediated Ras antagonism, even at the highest concentrations of doxycycline.
Mathematical model of competitive binding of Ras by R11.1.6 and Raf
In an effort to try to understand the lack of signaling inhibition, we developed a simple mathematical model to describe the system in which R11.1.6 competes with downstream effector proteins for binding of K-Ras ( Fig. 3a and Supplementary Fig. S4 ). For our analysis, we define (25)), and therefore is the greatest competitor for R11.1.6 binding. We then utilized this model to evaluate the feasibility of R11.1.6 inhibiting a significant portion of the K-Ras -Raf complexes that drive downstream signaling.
To determine the degree of inhibition possible as predicted by our model, we needed to quantify the number of copies of EGFP-R11.1.6 expressed by the cells upon induction with doxycycline. Quantification of fluorescence yielded an average across all cell lines of 1,300,000 molecules of EGFP-R11.1.6 per cell (Fig. 3b and Supplementary Fig. S5a ), which we confirmed by also quantifying based on quantitative western blots ( Supplementary Fig. S5b,c) .
Rather than defining the degree of inhibition as the fraction of K-Ras molecules occupied by R11.1.6 ( Supplementary Fig. S6a ), we normalized the number of K-Ras -Raf complexes that form in the presence of a given number of R11.1.6 molecules to the number that form if no inhibitor is present and defined this as the fraction of complexes that remain intact ( Supplementary Fig. S6b,c) . From this we then calculated the fraction of complexes that are inhibited by R11.1.6 ( Supplementary Fig. S6d ). Simulation over a range of Raf and R11.1.6 numbers per cell, with the number of K-Ras molecules held constant at 10 5 per cell (26), yields a heatmap of R11.1.6-mediated inhibition of K-Ras -Raf complex formation (Fig. 3c) . At approximately 10 6 copies of EGFP-R11.1.6 per cell and 10 4 copies of Raf (26), our model predicts only 16% inhibition of the K-Ras -Raf complexes that would otherwise form. This then could explain our negative results for signal inhibition with both the constitutively expressing and inducible cell lines, where we observed membrane localization of R11.1.6 ( Fig. 1a and 2a) and were able to co-immunoprecipitate Ras (Fig. 2b ) but failed to see signaling inhibition at the pERK level (Fig. 1b and 2c) . We postulate that the binding of R11.1.6 to Ras was sufficient to detect in our assays but perhaps insufficient to alter signaling. Modeling of the MAPK cascade has shown ERK to be ultrasensitive in its stimulusresponse curve (32) . Furthermore, pERK and pAKT have both been shown to be highly sensitive to upstream EGF stimulation, with significant signal amplification measured in response to minimal input (33) . Since Ras-driven signaling is amplified as the cascade proceeds, we propose that inhibition of the upstream input be near-complete to observe detectable changes downstream. The partial inhibition predicted for R11.1.6 by our simulations therefore would not suffice, which is consistent with our cell-line-based data.
Discussion
We previously described the engineering and characterization of R11.1.6, a high-affinity protein antagonist of K-Ras -Raf interaction (16) . In this work, we utilized R11.1.6 as a genetically encoded tool to evaluate the effects of Raf-competitive Ras antagonism in a panel of human cancer cell lines and found that despite measurable binding to endogenous Ras, R11.1.6 fails to inhibit signaling through both the MAPK and PI3K pathways. We developed a simple mathematical model describing the competition for Ras binding between R11. 
attained in our stable cell lines, only 16% inhibition of the K-Ras -Raf complexes that drive signaling may be achieved.
While our model can help explain the absence of R11.1.6-mediated signaling inhibition that we observed, it should be noted that the simulation is strongly dependent on the adjustment of K-Ras -Raf binding made to account for the high local concentration of Raf ( Supplementary   Fig. 4b ). Upon activation of Ras, either due to extracellular stimuli or mutation, Raf is recruited to the plasma membrane (27-31), its local concentration significantly increases, driving interaction with Ras and initiation of downstream signaling. It has been shown that 1,000-fold increases in local concentration of factors such as Sos are achieved due to membrane localization, and that these increases drive Ras signaling (34) . So in our model, we approximated the impact of Raf localization by adjusting the on-rate (k on,Raf ) for the second binding event in bivalent binding at a surface (35) while assuming the off-rate (k off,Raf ) is unchanged. This effective on-rate ultimately determines the degree of inhibition that can be achieved, which in the absence of Raf localization would be approximately 97% (Supplementary Fig. S7 ). Our model therefore suggests that the special feature of a very high local concentration of native ligand may make the pharmacological objective of competitive antagonism challenging.
Our observations propose that Raf-competitive Ras antagonism may be difficult, and while several small molecule and protein-based inhibitors have been shown to exert effects on Ras-driven signaling and proliferation, these do not necessarily conflict with our conclusions here. Small molecules that directly block interaction of Ras with Raf bind with weak affinity and exert their effects at concentrations in the hundreds of micromolar range (7) (8) (9) . Such high concentrations may translate into drug molecules on the order of 10 7 per cell, at which point our simulation predicts near complete inhibition (Fig. 3c) . Our own characterization of R11. the model HEK 293T system showed significant signaling inhibition, but only when plasmid encoding R11.1.6 was transfected at greater amounts than plasmid encoding K-Ras G12D (16) .
A recent self-internalizing antibody that blocks Ras interaction with downstream effector proteins showed efficacy in both cell-based assays and murine xenograft models (14) . Again, micromolar concentrations were required to observe effects, the bivalent IgG format may increase avidity significantly, and it is possible the antibody constant region contributed function via intracellular Fc receptors, analogous to that observed for intracellular antibody-bound pathogens (36) . Finally, a single antibody VH domain engineered to bind mutant H-Ras was shown to compete with effector proteins, but only exhibited efficacy when a membranelocalizing peptide was appended (12).
Pharmacological inhibition of Ras-driven tumors continues to be challenging, and while significant progress has been made over the years, the Ras problem is far from solved. Our findings may help shed light on a particular difficulty of interrupting this signaling axis and the potential hurdles that must be overcome in competitive Ras antagonism. Perhaps alternative approaches, such as allosteric antagonists (13), covalent allele-specific G12C inhibitors (37, 38) LS180  colon  G12D  HPAF-II  pancreas  G12D  SW48 G12D  colon  G12D  Calu-1  lung  G12C  NCI-H23  lung  G12C  SW48 G12C  colon  G12C  SW48 G12V  colon  G12V  PA-TU-8902  pancreas  G12V  PA-TU-8988T pancreas G12V 
